This week, senior Biden-Harris Administration officials again met with manufacturers of RSV immunizations including Sanofi and AstraZeneca and their partners. During the meeting, manufacturers discussed recent studies showing significant decreases in hospitalization rates among infants who received Nirsevimab. Senior administration officials and manufacturers also discussed the processes for continuing to update data on the safety and effectiveness of this immunization, as well as efforts to ensure continued availability of infant RSV immunizations in the US for the remainder of this season. At the urging of the Administration and in response to unprecedented requests for these immunizations, RSV manufacturers made 307,000 additional doses available to families, increasing supply and expediting availability. Manufacturers also described their work to ensure availability of RSV doses for infants ahead of the 2024-2025 respiratory season.

###